Compartmental absorption modeling and site of absorption studies to determine feasibility of an extended-release formulation of an HIV-1 attachment inhibitor phosphate ester prodrug.

Author: BrownJonathan, ChienCaly, DennisAndrew, DollWalter, GraselaDennis, NettlesRichard E, PageRichard, SandeferErik, TimminsPeter, ZhuLi

Paper Details 
Original Abstract of the Article :
BMS-663068 is a phosphonooxymethyl ester prodrug under development for the treatment of HIV/AIDS. The prodrug is designed to overcome the solubility-limited bioavailability of the active moiety, BMS-626529. BMS-663068 is not absorbed from the gastrointestinal (GI) tract and requires enzymatic conver...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://pubmed.ncbi.nlm.nih.gov/23681563

データ提供:米国国立医学図書館(NLM)

Optimizing HIV Treatment with Extended-Release Formulations

This study focuses on improving the delivery of a drug called BMS-663068, designed to treat HIV/AIDS. The researchers are trying to develop an extended-release formulation of this drug that can effectively reach the body's cells and combat the virus. The study investigates the absorption of the drug in different parts of the gastrointestinal tract and employs computer models to predict the feasibility of an extended-release formulation. The research also investigates the potential of this approach to reach desired blood levels of the active drug. The study concludes that extended-release formulations may be a promising avenue for improving the treatment of HIV/AIDS.

Modeling the Potential for Extended-Release

This study provides valuable insights into the development of extended-release formulations for HIV drugs. The researchers employed compartmental absorption modeling to predict the feasibility of such formulations, suggesting that extended-release delivery could be a valuable strategy in HIV treatment. These findings underscore the importance of meticulous drug delivery design in achieving optimal therapeutic outcomes.

Impact on HIV Treatment

The development of effective extended-release formulations for HIV medications could have a significant impact on patient care. Such formulations could provide sustained drug levels, potentially leading to improved treatment efficacy and reducing the frequency of medication administration. This research has the potential to contribute to the long-term management of HIV and enhance the quality of life for people living with the virus.

Dr.Camel's Conclusion

This study is like finding a hidden wellspring in a parched desert, providing a new source of water for the fight against HIV. Extended-release formulations offer a potential oasis for patients, providing a more convenient and effective means of managing the virus.

Date :
  1. Date Completed 2013-12-03
  2. Date Revised 2019-04-11
Further Info :

Pubmed ID

23681563

DOI: Digital Object Identifier

S0022-3549(15)31057-1

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.